Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327259 | 0.83 | DGAT1 (0.42) | ALDH1A1TSHRMMP8DGAT1HSD17B10 | |
| SCHEMBL17085265 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TSHRTHRBMMP8CYP4F2 | |
| SCHEMBL16368784 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 | |
| SCHEMBL16368829 | 0.78 | DGAT1 (0.50) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 | |
| SCHEMBL9752808 | 0.74 | DGAT1 (0.39) | ALDH1A1TSHRMMP8DGAT1 | |
| SCHEMBL16368798 | 0.74 | CYP4F2 (0.38) | ALDH1A1TSHRCYP4F2CYP4A11TP53 | |
| SCHEMBL14931670 | 0.74 | TSHR (0.40) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 | |
| SCHEMBL12535669 | 0.73 | TSHR (0.36) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 | |
| SCHEMBL12126262 | 0.73 | TSHR (0.36) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 | |
| SCHEMBL9923562 | 0.73 | TSHR (0.36) | ALDH1A1TSHRTHRBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | ALDH1A1 239/4885TSHR 2660/4885THRB 2491/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | ALDH1A1 239/4885TSHR 2660/4885THRB 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.